07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

NanoString sales and marketing update

NanoString said Medicare administrative contractor Palmetto GBA LLC (Columbia, S.C.) issued a final local coverage determination (LCD) recommending coverage of NanoString’s Prosigna Breast Cancer Prognostic Gene Signature Assay . The LCD takes effect Oct. 1....
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Prosigna Breast Cancer Prognostic Gene Signature Assay regulatory update

FDA approved an updated label for NanoString’s Prosigna Breast Cancer Prognostic Gene Signature Assay to include information on the observed risk of distant recurrence in postmenopausal women with estrogen receptor-positive, early stage breast cancer 5-10...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Prosigna Breast Cancer Prognostic Gene Signature Assay regulatory update

Australia’s Therapeutic Goods Administration ( TGA ) approved NanoString’s Prosigna Breast Cancer Prognostic Gene Signature Assay for use as a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with hormone receptor-positive...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Prosigna Breast Cancer Prognostic Gene Signature Assay regulatory update

Health Canada approved NanoString's Prosigna Breast Cancer Prognostic Gene Signature Assay for use as a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women who have undergone surgery in conjunction with locoregional...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

LabCorp, NanoString sales and marketing update

LabCorp launched NanoString's Prosigna Breast Cancer Prognostic Gene Signature Assay in the U.S. for use as a prognostic indicator for distant recurrence-free survival at 10 years. The breast cancer intrinsic subtyping assay is indicated in...
02:02 , Jan 14, 2014 |  BC Extra  |  Financial News

NanoString proposes $55 million follow-on

Diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) proposed to raise $55 million in a follow-on underwritten by JPMorgan; Morgan Stanley; Leerink; and Baird. Last year, NanoString launched its Prosigna Breast Cancer Prognostic Gene Signature Assay in...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

NanoString sales and marketing update

NanoString launched the nCounter Dx Analysis System for use in high-complexity, CLIA-certified, U.S. laboratories. The system runs the company's Prosigna Breast Cancer Prognostic Gene Signature Assay , which has 510(k) clearance in the U.S. for...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Prosigna Breast Cancer Prognostic Gene Signature Assay regulatory update

NanoString said FDA granted 510(k) clearance for Prosigna Breast Cancer Prognostic Gene Signature Assay for use as a prognostic indicator for distant recurrence-free survival at 10 years. The breast cancer intrinsic subtyping assay is indicated...
00:45 , Jun 27, 2013 |  BC Extra  |  Financial News

NanoString raises $54 million in IPO

Shares of diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) slid $1.94 (19%) to $8.06 in the company's first day of trading on Wednesday. NanoString raised $54 million through the sale of its proposed 5.4 million shares...
00:22 , Jun 14, 2013 |  BC Extra  |  Financial News

NanoString sets IPO range

Diagnostics company NanoString Technologies Inc. (Seattle, Wash.) amended its IPO and now plans to sell 5.4 million shares at $13-$15. At the $14 midpoint, NanoString would raise $75.6 million and be valued at $204.3 million....